Cargando…

Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy

BACKGROUND: Drug combinations of the proteasome inhibitor bortezomib with cytotoxic chemotherapy are currently evaluated in phase 2 and 3 trials for the treatment of paediatric acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL). METHODS: We investigated whether expression ratios of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niewerth, Denise, Kaspers, Gertjan J. L., Jansen, Gerrit, van Meerloo, Johan, Zweegman, Sonja, Jenkins, Gaye, Whitlock, James A., Hunger, Stephen P., Lu, Xiaomin, Alonzo, Todd A., van de Ven, Peter M., Horton, Terzah M., Cloos, Jacqueline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011854/ https://www.ncbi.nlm.nih.gov/pubmed/27599459 http://dx.doi.org/10.1186/s13045-016-0312-z

Ejemplares similares

P329: HIGH IMMUNOPROTEASOME ACTIVITY AS NOVEL INDICATOR FOR SENSITIVITY TO BORTEZOMIB-CONTAINING CHEMOTHERAPY IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM CHILDREN’S ONCOLOGY GROUP TRIAL AALL1231
por: Roeten, Margot, et al.
Publicado: (2023)

Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors
por: Franke, Niels E., et al.
Publicado: (2016)

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines
por: Niewerth, Denise, et al.
Publicado: (2014)

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
por: Roeten, Margot S.F., et al.
Publicado: (2021)

(Immuno)proteasomes as therapeutic target in acute leukemia
por: Cloos, Jacqueline, et al.
Publicado: (2017)

Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis
por: de Groot, Karina A, et al.
Publicado: (2015)

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors
por: Verbrugge, Sue Ellen, et al.
Publicado: (2013)

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
por: Zaal, Esther A., et al.
Publicado: (2017)

Acute myeloid leukaemia niche regulates response to L‐asparaginase
por: Kaspers, Gertjan J. L.
Publicado: (2019)

Quantitation of chemosensitivity in acute myelocytic leukaemia.
por: Lihou, M. G., et al.
Publicado: (1983)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Positioning of proteasome inhibitors in therapy of solid malignancies
por: Roeten, Margot S. F., et al.
Publicado: (2017)

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model‐Based Support for Body Surface Area‐Based Dosing Over the 2‐ to 16‐Year Age Range
por: Hanley, Michael J., et al.
Publicado: (2017)

In HPV-Positive HNSCC Cells, Functional Restoration of the p53/p21 Pathway by Proteasome Inhibitor Bortezomib Does Not Affect Radio- or Chemosensitivity()()
por: Seltzsam, Steve, et al.
Publicado: (2018)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
por: Kagdi, Huseini, et al.
Publicado: (2014)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib
por: Gelman, Julia S., et al.
Publicado: (2013)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
por: Steverding, Dietmar, et al.
Publicado: (2009)

Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
por: Schlesser, Camille, et al.
Publicado: (2022)

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group
por: Aplenc, Richard, et al.
Publicado: (2020)

Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2015)

Proteasome inhibition by bortezomib: A left hook and a right punch
por: Roelofs, Jeroen
Publicado: (2015)

Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting
por: Penna, Fabio, et al.
Publicado: (2015)

Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
por: Wu, Yi-Xin, et al.
Publicado: (2016)

Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells
por: Jansen, Gerrit, et al.
Publicado: (2023)

The usefulness of growth hormone treatment for psychological status in young adult survivors of childhood leukaemia: an open-label study
por: Huisman, Jaap, et al.
Publicado: (2008)

The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia
por: Sin, Chun-fung, et al.
Publicado: (2021)

Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical Trial
por: Astakhova, Tatiana M., et al.
Publicado: (2018)

Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia.
por: Sargent, J. M., et al.
Publicado: (1989)

An assessment of a short-term tumour chemosensitivity assay in chronic lymphocytic leukaemia.
por: Bosanquet, A. G., et al.
Publicado: (1983)

Hypermethylation of the FANCC and FANCL Promoter Regions in Sporadic Acute Leukaemia
por: Hess, C. J., et al.
Publicado: (2008)

The ubiquitin–proteasome system as a molecular target in solid tumors: an update on bortezomib
por: Milano, A, et al.
Publicado: (2009)

Hypoxia Enhances the Senescence Effect of Bortezomib—The Proteasome Inhibitor—On Human Skin Fibroblasts
por: Krętowski, Rafał, et al.
Publicado: (2014)

Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
por: Cerruti, Fulvia, et al.
Publicado: (2017)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets
por: Ghansah, Harriet, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vp8fjfrnrh38a7hu5fovlsjsqg